– USA, CA – ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis, has closed on a Series D financing of $55 million led by SR One with participation from RA Capital Management, and one other U.S.-based, healthcare-focused fund, as well as an existing investor, Deerfield Management.
Concurrent with this funding, the company appointed Dr. Rajeev Dadoo, managing partner of SR One, and Dr. Peter Kolchinsky, managing partner and founder of RA Capital to the board of directors, building on the recent appointment of Brent Saunders, CEO, president, and chairman of Vesper Healthcare Acquisition Corp.
“ARS is very pleased to have gained the support of a top tier group of investors including SR One, Deerfield, RA Capital, and a leading long-term public equity investment fund focused on the life sciences; this additional funding will allow us to focus on pre-launch activities for Neffy and additional research and development for a second indication for nasal epinephrine that we believe can add significant value to the ARS portfolio. This investment advances further work to prepare for launch of a reliable, easy-to-use, needle-free option for the treatment of a severe allergic reaction”, said founder and CEO, Richard Lowenthal.
About Dr. Rajeev Dadoo
Dr. Rajeev Dadoo joined SR One in 2004 and has experience in investing in the therapeutics space and healthcare-technology companies. His prior roles have included working in the Competitive Excellence group at GSK on various global projects and Genentech in technology and clinical development.
About Dr. Peter Kolchinsky
Dr. Peter Kolchinsky co-founded RA Capital in 2004 and is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. Peter is a strong advocate for patients with severe allergies, working on multiple projects with FARE, which is the largest private funder of food allergy research, including supporting FARE research grants and hosting one of its educational podcasts, “Future in Sight,” focused on exploring innovations in food allergies.
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The Company is developing Neffy, an intranasal epinephrine spray with a unique absorption technology that could be easy-to-use, convenient, and more reliable for patients and loved ones at risk of severe allergic reactions to food, medications, and insect bites that could lead to life-threatening anaphylaxis.
For more information: https://ars-pharma.com/
About SR One
SR One Capital Management is a trans-Atlantic venture capital firm that partners with entrepreneurs to build companies with a mission to address significant unmet needs in medicine and healthcare.
For more information: https://www.srone.com/
About RA Capital Management
RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics.
For more information: https://www.racap.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
